久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國(guó)CardioMEMS
CardioMEMS是一個(gè)醫(yī)療器械公司已開發(fā)并正在商業(yè)化專有無(wú)線傳感和人體通信技術(shù)。我們的技術(shù)平臺(tái)，目的是改善諸如動(dòng)脈瘤，心臟衰竭，高血壓，嚴(yán)重慢性心血管疾病的管理。我們的微型無(wú)線傳感器可以植入用微創(chuàng)技術(shù)和傳輸心輸出量，血壓和心率數(shù)據(jù)，是至關(guān)重要的病人管理。我們的傳感器被設(shè)計(jì)成永久性心臟和血管由于其體積小，耐用性植入，以及電線和電池不足。利用射頻或RF，能源，我們的傳感器傳送實(shí)時(shí)數(shù)據(jù)外部電子閱讀器，然后傳達(dá)這一信息對(duì)病人的醫(yī)生。我們相信頻繁，點(diǎn)播，重要信息的實(shí)時(shí)監(jiān)測(cè)病人能夠主動(dòng)管理，持有減少住院的承諾，改善病人的生活質(zhì)量和提供更有效率和成本效益的醫(yī)療。
所作的發(fā)言，本新聞稿中期待在時(shí)間或表達(dá)信念，預(yù)期或?qū)ξ磥?lái)的希望或預(yù)期出現(xiàn)的結(jié)果都是前瞻性聲明。阿如產(chǎn)品開發(fā)和商業(yè)化的努力預(yù)計(jì)何時(shí)或任何臨床試驗(yàn)，最終的臨床結(jié)果和知覺或本公司的產(chǎn)品，市場(chǎng)和醫(yī)生的產(chǎn)品，知識(shí)產(chǎn)權(quán)保護(hù)驗(yàn)收的實(shí)際優(yōu)勢(shì)的結(jié)果，可能帶來(lái)的風(fēng)險(xiǎn)的風(fēng)險(xiǎn)和不確定性和競(jìng)爭(zhēng)產(chǎn)品可能導(dǎo)致實(shí)際事件產(chǎn)生不利不同的期望表示在這些前瞻性聲明。
CardioMEMS是CardioMEMS，公司的注冊(cè)商標(biāo)

美國(guó)CardioMEMS公司最近成功融資兩千兩百一十萬(wàn)美元，用于重要的臨床試驗(yàn)。CardioMEMS正在開發(fā)一種能夠植入人體來(lái)控制心力衰竭、動(dòng)脈瘤、高血壓等嚴(yán)重的慢性心血管疾病的無(wú)線器件。以上投資來(lái)自公司現(xiàn)有的投資者，包括Arcapita Ventures、Boston Millennia Partners、 Foundation Medical Partners，是其計(jì)劃的二千九百五十五萬(wàn)元融資的一部分。

資金將用于CHAMPION臨床試驗(yàn)，評(píng)估CardioMEMS心力衰竭壓力監(jiān)控系統(tǒng)。臨床試驗(yàn)將在美國(guó)的65個(gè)心血管中心進(jìn)行。

CardioMEMS的心力衰竭傳感器是一個(gè)微型器件，將用導(dǎo)管的方式植入肺動(dòng)脈。肺動(dòng)脈的壓力則利用公司的專利電子監(jiān)控系統(tǒng)測(cè)量并顯示。遵照程序，病人在家里無(wú)線監(jiān)測(cè)其肺動(dòng)脈壓力，數(shù)據(jù)立即傳送到安全的數(shù)據(jù)庫(kù)，供醫(yī)生通過(guò)CardioMEMS的網(wǎng)站實(shí)時(shí)監(jiān)測(cè)。

CardioMEMS預(yù)期在2010年尋求FDA對(duì)其CHAMPION心力衰竭傳感器的認(rèn)證。

在2007年，CardioMEMS融資三千三百萬(wàn)美元。

CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients. Due to their small size, durability, and lack of wires and batteries, our sensors are designed to be permanently implanted into the cardiovascular system. Using radiofrequency, or RF, energy, our sensors transmit real-time data to an external electronics module, which then communicates this information to the patient’s physician.

Our first commercial device, the EndoSure? Wireless AAA Pressure Measurement System, is comprised of an implanted sensor and an external electronics module. The EndoSure? sensor is inserted during the minimally invasive endovascular repair of abdominal aortic aneurysms, or AAA, via a catheter into a patient’s aneurysm sac and measures and communicates pressure information to an external electronics module from inside the sac. We are adapting the technology used for our EndoSure? system for use in patients with heart failure and in patients with hypertension. Our heart failure and hypertension sensors will be further miniaturized versions of the EndoSure? sensor that use the same materials, manufacturing methods and operational concepts as the EndoSure? sensor.